MoonLake Immunotherapeutics (MLTX) Tops Q3 EPS by 5c

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q3 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23).

For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• The LGL Group (LGL) Misses Q2 EPS by 8c